PMID- 31951028
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 60
IP  - 3
DP  - 2020 Mar
TI  - The effect of serum pretreatment regimens for the detection of HLA class I 
      antibodies in platelet-refractory patients.
PG  - 488-497
LID - 10.1111/trf.15666 [doi]
AB  - BACKGROUND: Single antigen bead (SAB) assays are used to identify human leukocyte 
      antigen (HLA) antibodies in patients with platelet refractoriness due to HLA 
      Class I alloimmunization. Some laboratories use serum pretreatment regimens to 
      eliminate interference from immunoglobulin M antibodies and complement. These 
      modifications may contribute to interlaboratory variability, which is a 
      recognized problem with the SAB assay. STUDY DESIGN AND METHODS: Five patients' 
      sera were overnight shipped to 12 laboratories in the United States and 
      internationally. Recipients used their lab's SAB procedure to identify HLA Class 
      I antibodies. The resultant mean fluorescence intensity (MFI) data were compared 
      by instrumentation, bead lot, and pretreatment regimens. Laboratory-specific 
      cutoffs for positive antibodies were applied to the results. RESULTS: 
      Interlaboratory variability for MFI values appears to be associated with 
      different pretreatment regimens. The coefficient of variation (CV) of MFI from 
      samples pretreated with ethylenediaminetetraacetic acid, dithiothreitol, or heat 
      inactivation (EDHI) were similar, ranging from 14% to 56% (mean, 22%). For 
      samples with no pretreatment, the CVs were significantly higher than EDHI-treated 
      samples, ranging from 25% to 74% (mean, 39%; 95% confidence interval, 
      12.10-21.90; p < 0.0001). An intralaboratory comparison of pretreatment regimens 
      confirmed these findings. Some positive antibody specificities present in 
      EDHI-treated samples were negative in corresponding samples with no pretreatment 
      when laboratory-specific cutoffs for positive antibodies were applied. 
      CONCLUSION: Our results show that greater interlaboratory precision can be 
      achieved when samples are pretreated with EDHI as opposed to no pretreatment, 
      likely because these pretreatments eliminate interference from inhibitors. 
      Inhibitors may mask antibodies, leading to missed (or uncalled) specificities 
      when no pretreatment is used.
CI  - (c) 2020 AABB.
FAU - Tumer, Gizem
AU  - Tumer G
AD  - Department of Laboratory Medicine and Pathology, University of Minnesota, 
      Minneapolis, Minnesota.
FAU - Gniadek, Thomas
AU  - Gniadek T
AD  - Department of Pathology, NorthShore University Health System, Evanston, Illinois.
FAU - Baye, Jennifer
AU  - Baye J
AD  - Histocompatibility and Immunology Laboratory, Fairview, Minneapolis, Minnesota.
FAU - Pena, Ryan
AU  - Pena R
AD  - Beth Israel Deaconess Hospital, Boston, Massachusetts.
FAU - Warner, Paul
AU  - Warner P
AD  - Bloodworks Northwest, Seattle, Washington.
FAU - Fung, Mark
AU  - Fung M
AD  - HLA Laboratory, The University of Vermont Medical Center, Burlington, Vermont.
FAU - Beaudin, Lynette
AU  - Beaudin L
AD  - Canadian Blood Services, Manitoba, Canada.
FAU - Dunckley, Heather
AU  - Dunckley H
AD  - New Zealand Blood Service, Auckland, New Zealand.
FAU - Gandhi, Manish
AU  - Gandhi M
AUID- ORCID: 0000-0001-7210-1909
AD  - Mayo Clinic, Rochester, Minnesota.
FAU - Gathof, Birgit
AU  - Gathof B
AD  - University of Cologne, Koln, Germany.
FAU - Hsu, Susan
AU  - Hsu S
AD  - American Red Cross Penn Jersey, Philadelphia, Pennsylvania.
FAU - Klohe, Ellen
AU  - Klohe E
AD  - HLA Laboratory, Vitalant, Spokane, Washington.
FAU - Marcus, Nalaja
AU  - Marcus N
AD  - HLA Laboratory, Vitalant, Phoenix, Arizona.
FAU - Bamert, Roberta
AU  - Bamert R
AD  - American Red Cross Southern California Region, Pomona, California.
FAU - Sims, Shona
AU  - Sims S
AD  - American Red Cross, Portland, Oregon.
FAU - Takanashi, Minoko
AU  - Takanashi M
AD  - Japanese Red Cross Society Blood Service Headquarters, Tokyo, Japan.
FAU - Wendel, Silvano
AU  - Wendel S
AD  - Hospital Sirio Libanes, Sao Paulo, Brazil.
FAU - Cohn, Claudia S
AU  - Cohn CS
AUID- ORCID: 0000-0001-9847-0470
AD  - Department of Laboratory Medicine and Pathology, University of Minnesota, 
      Minneapolis, Minnesota.
CN  - Biomedical Excellence for Safer Transfusion (BEST) Collaborative
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200117
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Isoantibodies)
RN  - 9G34HU7RV0 (Edetic Acid)
RN  - T8ID5YZU6Y (Dithiothreitol)
SB  - IM
MH  - Antibody Specificity
MH  - Blood Platelets/drug effects/metabolism
MH  - Dithiothreitol/pharmacology
MH  - Edetic Acid/pharmacology
MH  - Female
MH  - HLA Antigens/metabolism
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunoglobulin M/metabolism
MH  - Isoantibodies/*immunology
MH  - Male
EDAT- 2020/01/18 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/01/18 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2019/12/26 00:00 [revised]
PHST- 2019/12/27 00:00 [accepted]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2020/01/18 06:00 [entrez]
AID - 10.1111/trf.15666 [doi]
PST - ppublish
SO  - Transfusion. 2020 Mar;60(3):488-497. doi: 10.1111/trf.15666. Epub 2020 Jan 17.